Share Page:

Volume 31 , Issue 6
November/December 2016

Pages 1298–1302

Preliminary Findings on the Role of Sclerostin in the Osseointegration Process Around Titanium Implants

Fábio Luiz da Silva, DDS, MS/Carlos Alberto Alves Maced, DDS, MS/Daiane Cristina Peruzzo, DDS, MS, PhD/Victor Ângelo Martins Montalli, DDS, MS, PhD/Poliana Mendes Duarte, DDS, MS, PhD/Marcelo Henrique Napimoga, DDS, MS, PhD

PMID: 27861654
DOI: 10.11607/jomi.5093

Purpose: Studies have recognized the importance of Wnt/β-catenin signals in osteoblastogenesis. Sclerostin is a glycoprotein product of the SOST gene that inhibits Wnt/β-catenin signaling and reduces osteoblastogenesis. To date, there is little evidence regarding the role of the Wnt/β-catenin pathway and its inhibitors in the osseointegration process. Therefore, the aim of this study was to evaluate the expression of sclerostin in bone healing around titanium implants inserted in rats. Materials and Methods: Fifteen Wistar rats received an implant with primary stability in a tibia, while the contralateral tibia received an implant without primary stability, representing experimental models of implant success and failure, respectively. Animals were then euthanized 7, 14, or 21 days later (five each day). Immunohistochemistry was used to evaluate the specimens for sclerostin-positive cells. Results: The proportion of cells positive for sclerostin was significantly higher around implants without primary stability than those with primary stability at 7 and 14 days after implant placement (P < .05). There were no differences between groups for the proportion of cells positive for sclerostin at 21 days after implant insertion (P > .05). Conclusion: Sclerostin expression is upregulated around implants inserted without primary stability, in comparison with that around implants inserted with primary stability, in the tibia of rats. This preliminary evidence reinforces the importance of primary implant stability from the biologic viewpoint.

Full Text PDF File | Order Article


Get Adobe Reader
Adobe Acrobat Reader is required to view PDF files. This is a free program available from the Adobe web site.
Follow the download directions on the Adobe web site to get your copy of Adobe Acrobat Reader.


© 2017 Quintessence Publishing Co, Inc JOMI Home
Current Issue
Ahead of Print
Author Guidelines
Accepted Manuscripts
Submission Form
Quintessence Home
Terms of Use
Privacy Policy
About Us
Contact Us